{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T08:45:38Z","timestamp":1759481138140},"reference-count":35,"publisher":"The Journal of Rheumatology","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2012,3]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To describe clinical fracture rates, back pain, and health-related quality of life (HRQOL) in postmenopausal women with osteoporosis who are receiving glucocorticoids (GC), during a 36-month study of teriparatide treatment for up to 18 months, with an additional 18-month followup period when patients were receiving other osteoporosis medications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>A prospective, multinational, observational study. Data for clinical fractures, back pain (by visual analog scale; VAS) and HRQOL (by EQ-5D) were collected over 36 months. Fracture data were summarized in 6-month segments and analyzed using logistic regression with repeated measures. Changes from baseline in back pain VAS and EQ-VAS were analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Of 1581 enrolled women with followup data, 294 (18.6%) had antecedents of GC use. Of these, 49 (16.7%) patients sustained a total of 69 fractures during the 36-month study period. Adjusted odds of fracture were significantly decreased during the last year of followup compared with the first 6 months of teriparatide treatment: an 81% decrease in the 24 to &lt; 30-month period (p &lt; 0.05), and an 89% decrease in the 30 to &lt; 36-month period (p &lt; 0.05). There were significant reductions in back pain and improvements in HRQOL in both groups of GC users and nonusers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>Postmenopausal women with severe osteoporosis receiving GC, who were treated with teriparatide for up to 18 months, showed a reduced incidence of clinical fractures during the third year while receiving sequential osteoporosis treatments compared with the first 6 months, together with reduced back pain and improved HRQOL. Our results should be interpreted in the context of an uncontrolled observational study in a routine clinical setting.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.110947","type":"journal-article","created":{"date-parts":[[2012,1,16]],"date-time":"2012-01-16T01:23:11Z","timestamp":1326676991000},"page":"600-609","source":"Crossref","is-referenced-by-count":29,"title":["Effectiveness of Teriparatide in Postmenopausal Women with Osteoporosis and Glucocorticoid Use: 3-Year Results from the EFOS Study"],"prefix":"10.3899","volume":"39","author":[{"given":"DIMITRIOS","family":"KARRAS","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"IVAYLO","family":"STOYKOV","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"WILLEM F.","family":"LEMS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"BENTE L.","family":"LANGDAHL","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d6STEN","family":"LJUNGGREN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ANNABEL","family":"BARRETT","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. BERNARD","family":"WALSH","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ASTRID","family":"FAHRLEITNER-PAMMER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"GERALD","family":"RAJZBAUM","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"FRANZ","family":"JAKOB","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"FERNANDO","family":"MARIN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2012,1,15]]},"reference":[{"key":"2018112909275594000_39.3.600.1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-007-0394-0"},{"key":"2018112909275594000_39.3.600.2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22975"},{"key":"2018112909275594000_39.3.600.3","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2009.259"},{"key":"2018112909275594000_39.3.600.4","doi-asserted-by":"publisher","DOI":"10.1002\/art.11283"},{"key":"2018112909275594000_39.3.600.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa071408"},{"key":"2018112909275594000_39.3.600.6","doi-asserted-by":"publisher","DOI":"10.1002\/art.24879"},{"key":"2018112909275594000_39.3.600.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2008.09.030"},{"key":"2018112909275594000_39.3.600.8","doi-asserted-by":"publisher","DOI":"10.1185\/030079908X261087"},{"key":"2018112909275594000_39.3.600.9","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-009-9299-6"},{"key":"2018112909275594000_39.3.600.10","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-010-1498-5"},{"key":"2018112909275594000_39.3.600.11","unstructured":"Forsteo (teriparatide) . Summary of product characteristics. London: European Medicines Agency; 2011. [Internet. Accessed November 23, 2011.] Available from: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000425\/human_med_000798.jsp&murl=menus\/medicines\/medicines.jsp&jsenabled=true"},{"key":"2018112909275594000_39.3.600.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)90025-5"},{"key":"2018112909275594000_39.3.600.13","doi-asserted-by":"publisher","DOI":"10.3109\/07853890109002087"},{"key":"2018112909275594000_39.3.600.14","unstructured":"Szende A Williams A , editors. Measuring self-reported population health: An international perspective based on EQ-5D. Budapest:SpringMed; 2004."},{"key":"2018112909275594000_39.3.600.15","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/73.1.13"},{"key":"2018112909275594000_39.3.600.16","doi-asserted-by":"crossref","unstructured":"Hosmer DW Lemeshow S . Applied logistic regression. 2nd ed. New York:Wiley; 2000.","DOI":"10.1002\/0471722146"},{"key":"2018112909275594000_39.3.600.17","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.040134"},{"key":"2018112909275594000_39.3.600.18","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2000.15.6.993"},{"key":"2018112909275594000_39.3.600.19","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-009-0005-4"},{"key":"2018112909275594000_39.3.600.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2009.06.030"},{"key":"2018112909275594000_39.3.600.21","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2001.16.1.97"},{"key":"2018112909275594000_39.3.600.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2010.05.019"},{"key":"2018112909275594000_39.3.600.23","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.253"},{"key":"2018112909275594000_39.3.600.24","doi-asserted-by":"publisher","DOI":"10.1038\/ncpendmet0838"},{"key":"2018112909275594000_39.3.600.25","doi-asserted-by":"publisher","DOI":"10.1002\/art.30135"},{"key":"2018112909275594000_39.3.600.26","doi-asserted-by":"publisher","DOI":"10.1210\/en.136.8.3632"},{"key":"2018112909275594000_39.3.600.27","doi-asserted-by":"publisher","DOI":"10.1172\/JCI6610"},{"key":"2018112909275594000_39.3.600.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra067395"},{"key":"2018112909275594000_39.3.600.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2008.03.003"},{"key":"2018112909275594000_39.3.600.30","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.061011"},{"key":"2018112909275594000_39.3.600.31","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.090416"},{"key":"2018112909275594000_39.3.600.32","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-009-0917-y"},{"key":"2018112909275594000_39.3.600.33","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20295"},{"key":"2018112909275594000_39.3.600.34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200105103441904"},{"key":"2018112909275594000_39.3.600.35","first-page":"CD000952","article-title":"Calcium and vitamin D for corticosteroid-induced osteoporosis","volume":"2","author":"Homik","year":"2000","journal-title":"Cochrane Database Syst Rev"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.110947","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T18:14:08Z","timestamp":1543515248000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.110947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,15]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2012,3,1]]},"published-print":{"date-parts":[[2012,3]]}},"alternative-id":["10.3899\/jrheum.110947"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.110947","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,15]]}}}